Basilea starts phase 1/2 study FIDES-03 with derazantinib in patients with gastric cancer

NEXT STORY
GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease
PREV STORY
Kiadis and Gulf Coast Regional Blood Center announce collaboration to provide universal donor material for K-NK cell therapy programs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Agios Announces the Randomized Phase 3 ClarIDHy Trial of TIBSOVO® (ivosidenib) Achieved its Primary Endpoint in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

author_avatar
NASDAQ Market News

Pfizer and BioNTech Receive CHMP Positive Opinion for COVID-19 Vaccine Booster in the European Union

author_avatar
NASDAQ Market News

Global Bone Cement Mixer Devices Market Research Report (2021 to 2026) – by Type, End-user and Region

author_avatar
NASDAQ Market News